మా గ్రూప్ ప్రతి సంవత్సరం USA, యూరప్ & ఆసియా అంతటా 3000+ గ్లోబల్ కాన్ఫరెన్స్ ఈవెంట్లను నిర్వహిస్తుంది మరియు 1000 కంటే ఎక్కువ సైంటిఫిక్ సొసైటీల మద్దతుతో 700+ ఓపెన్ యాక్సెస్ జర్నల్లను ప్రచురిస్తుంది , ఇందులో 50000 మంది ప్రముఖ వ్యక్తులు, ప్రఖ్యాత శాస్త్రవేత్తలు ఎడిటోరియల్ బోర్డ్ సభ్యులుగా ఉన్నారు.
ఎక్కువ మంది పాఠకులు మరియు అనులేఖనాలను పొందే ఓపెన్ యాక్సెస్ జర్నల్స్
700 జర్నల్స్ మరియు 15,000,000 రీడర్లు ప్రతి జర్నల్ 25,000+ రీడర్లను పొందుతున్నారు
Brent Hodgkinson, Tianjiao Wang, Joshua Byrnes and Paul Scuffham
Background:
VZV is a vaccine preventable disease that has yet to be universally included in many countries vaccination schedules due to uncertainty over the cost-effectiveness of the vaccination strategies. Here we describe the results of a recently published systematic review of the literature that was conducted to summarise available evidence on the cost-effectiveness of VZV vaccination strategies.
Methods:
The systematic review was conducted in accordance with PRISMA guidelines and Cochrane methods.
Results:
Six cost-utility studies, all using dynamic transmission modelling (DTM) techniques were identified. All studies modelled a rapid decrease in VZV incidence following VZV vaccination and an increase in HZ incidence that could last for decades when exogenous boosting (EB) was assumed. The cost-effectiveness of VZV vaccination compared to no-vaccination ranged from being dominated when HZ increases lasted for >50 years to cost-effective ($7,000 to $61,000 in 2019 USD) and even dominant as the period where HZ incidence was elevated became shorter.
Conclusions:
The DTM models identified in the review are sensitive to EB assumptions and limited by requirements for homogeneity in infection risk within age groups. The use of agent-based models to account for the individual nature of infectiousness should be considered. Early work using an agent-based model has supported the results of DTM models identified in the original review.